Page breadcrumb nav

VAERS Report 2156709

Case Report Section

Détails du rapport Vaer

Âge: 48 ans

Genre: Female

Région : Outside US

Patient décédé?
Non
Renseignements sur les vaccins

Nom: COVID19 (COVID19 (PFIZER-BIONTECH))

Type : Coronavirus 2019 vaccine

Fabricant: PFIZER

Lot: unknown


Date de réception du rapport
2022-03-04
Date à laquelle le formulaire est complèté
Date de vaccination
2022-02-05
Date d’apparition
0
Nombre de jours (date d’apparition – date de vaccination)
0
Description de l’événement indésirable

after 3 days rash developed on face ears and neck; primary immunisation: dose 1: astrazeneca, dose 2: pfizer covid vaccine; primary immunisation: dose 1: astrazeneca, dose 2: pfizer covid vaccine; high temperature; pain on the injection site; face red; feeling hot; sweating; face itchy; eyes swollen; eyes red; eyes itchy; face swollen; this is a spontaneous report received from a contactable reporter (consumer) from the regulatory authority. the reporter is the patient. regulatory number: gb-mhra-webcovid-202202141412484000-l5qpe (agency). other case identifier: gb-mhra-adr 26601665 (agency). a 48 year-old female patient received bnt162b2 (comirnaty), administration date 05feb2022 (batch/lot number: unknown) at the age of 48 years as dose 2, single for covid-19 immunisation. relevant medical history included: "period pains" (unspecified if ongoing), notes: anxiety and depression, severe periods pains on treatment for both conditions; "immunodeficiency" (unspecified if ongoing), notes: has an illness or condition, which reduces the immune response (e.g. immunodeficiency); "anxiety" (unspecified if ongoing), notes: anxiety and depression, severe periods pains on treatment for both conditions; "depression" (unspecified if ongoing), notes: anxiety and depression, severe periods pains on treatment for both conditions. the patient's concomitant medications were not reported. vaccination history included: covid-19 vaccine astrazeneca (dose 1), administration date: 14jun2021, for covid-19 immunisation. the following information was reported: off label use (medically significant), interchange of vaccine products (medically significant) all with onset 05feb2022, outcome "unknown" and all described as "primary immunisation: dose 1: astrazeneca, dose 2: pfizer covid vaccine"; feeling hot (medically significant) with onset feb2022, outcome "not recovered", described as "feeling hot"; hyperhidrosis (medically significant) with onset feb2022, outcome "not recovered", described as "sweating"; pyrexia (medically significant) with onset 05feb2022, outcome "not recovered", described as "high temperature"; vaccination site pain (medically significant) with onset feb2022, outcome "unknown", described as "pain on the injection site"; erythema (medically significant) with onset feb2022, outcome "unknown", described as "face red"; rash (medically significant) with onset 08feb2022, outcome "unknown", described as "after 3 days rash developed on face ears and neck"; pruritus (medically significant) with onset feb2022, outcome "unknown", described as "face itchy"; eye swelling (medically significant) with onset feb2022, outcome "unknown", described as "eyes swollen"; ocular hyperaemia (medically significant) with onset feb2022, outcome "unknown", described as "eyes red"; eye pruritus (medically significant) with onset feb2022, outcome "unknown", described as "eyes itchy"; swelling face (medically significant) with onset feb2022, outcome "unknown", described as "face swollen". the patient underwent the following laboratory tests and procedures: sars-cov-2 test: no - negative covid-19 test. patient had not tested positive for covid-19 since having the vaccine. clinical course: patient reported feeling hot, pain on the injection site ,sweating, face red then after 3 days rash developed on face, ears and neck, face and eyes swollen and red and itchy. patient had not had symptoms associated with covid-19. patient was not currently breastfeeding. patient was not enrolled in clinical trial. the report was unrelated to possible inflammation of the heart (myocarditis or pericarditis). no follow-up attempts are possible; information about lot/batch number cannot be obtained. no further information is expected

Données de laboratoire
test name: covid-19 virus test; result unstructured data: test result:no - negative covid-19 test
Liste des symptômes
hyperhidrosis eye pruritus pruritus rash feeling hot erythema pyrexia ocular hyperaemia interchange of vaccine products swelling face sars-cov-2 test vaccination site pain eye swelling off label use
Patient décédé?
Non
Date de décès
N/A
Anomalie congénitale
false
Vaccin administré par :
Other
Vaccin acheté par :
Inconnu
Visite d’un patient à l’urgence?
Non
Patient hospitalisé?
Non
Séjour à l’hôpital
Non
Nombre de jours à l’hôpital
Non spécifié
Invalidité permanente?
Non
Allergies:
na
Maladie actuelle
na